You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

65 search results for: biologics

expert video

UCARE 2023: Emerging Clinical Trial Data in CSU

13 min

Dermatology

Dr. Maurer explores current clinical data from leading emerging therapies in CSU.

expert video

How Interdisciplinary Communication and Collaboration Can Overcome Challenges in CSU Patient Management

10 min

Dermatology

Drs. Kim and Saini discuss the importance of interdisciplinary communication and collaboration in overcoming challenges in CSU patient management.

expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

5 min

Rhinology

Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.

videoanimation

GINA Asthma Decision Tree

17 min

Pulmonology

Walk through the GINA decision tree for severe asthma

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

18 min

Pulmonology

Prof. Monika Gappa presents the importance in assessment of lung function in pediatric patients alongside the associated patient burden.

expert video

The Current and Potential Future Roles of Biomarkers and Precision Medicine in CSU Clinical Management

11 min

Dermatology

Drs. Kim and Saini explore the potential future roles of biomarkers and precision medicine in CSU clinical management.

expert video

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

56 min

Dermatology

Experts discuss the latest evidence on how type 2 inflammation drives skin barrier dysfunction, affects the skin microbiome, and contributes to neuroimmune dysregulation in AD.

expert video

Skin Dysbiosis in AD

17 min

Dermatology

Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.

expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

10 min

Dermatology

Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.

expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

26 min

Type 2 Inflammation

Dr. Robert Bissonnette explains the role of type 2 inflammation in skin barrier dysfunction and how regulation of type 2 inflammation can normalize the skin barrier and potentially modify the disease with early intervention.

expert video

UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

1 min

Dermatology

Dr. Maurer summarises the implications of different modes of action of dupilumab, remibrutinib and barzolvolimab.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SudanChange country/region